 |
|
|
|
Vaccines at Statens Serum Institut
Statens Serum Institut has a long history of vaccine development. Today the Institute continues to offer the childhood vaccination program which provides free vaccination against 8 of the most serious diseases of childhood. Together with private practitioners, the Institute also offers advice on, and access to, vaccines for travellers, either in the clinic or at your own doctor. Travel vaccinations are not covered by the public health system.
Center for Vaccine Research
Center for Vaccine Research aims to form a critical mass of researchers involved in the fight against the global epidemic of TB, HIV, Malaria and Chlamydia.
These diseases are among the world’s greatest public health problems with an estimated 300 million new cases per year and more than 5 million deaths annually. This represents tremendous human suffering and a burden that prevents the development of the affected endemic communities.
The mission of Center for Vaccine Research is to improve human health by:
- Elucidating the mechanisms of immunity against human pathogens
- Identifying new antigenic determinants and virulence factors
- Development and evaluation of novel vaccines and adjuvants
- Training investigators in the field of vaccine research
Center for Vaccine Research has state of the art laboratories and animal facilities, including close links with the Department of Vaccine Development with a pilot plant for cGMP production of experimental vaccines. Center for Vaccine Research uses advanced molecular biology, genetic, and immunology techniques to develop new vaccines with an emphasis on tools which can be used by the world’s poorest nations, who suffer most from these diseases. The research is conducted in small groups focused on each disease as well as in groups working on the development of generic platform technologies such as new vaccine delivery systems and adjuvants.
As a result of many of these research activities, members of Center for Vaccine Research have generated more than 250 scientific publications over the last 10 years and they have developed technology resulting in more than 20 international patents on vaccines and adjuvant systems. New vaccines and diagnostic kits based on these studies are now in human trials or already entering the clinic.
|
|
|
|
|
|
|
|
|
|
|
